CCL

Összesen 9 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM041939
Első szerző:Barta Zsolt (belgyógyász, gasztroenterológus)
Cím:Pulse cyclophosphamide in steroid-resistant inflammatory bowel disease / Barta, Z., Zöld, E., Zeher, M.
Dátum:2007
ISSN:0269-2813
Tárgyszavak:Orvostudományok Klinikai orvostudományok szerkesztői levél
Megjelenés:Alimentary Pharmacology & Therapeutics. - 25 : 11 (2007), p. 1363-1364. -
További szerzők:Zöld Éva (1978-) (belgyógyász) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM007209
Első szerző:Kapitány Anikó (molekuláris biológus)
Cím:Diagnostic significance of HLA-DQ typing in patients with previous coeliac disease diagnosis based on histology alone / Kapitány A., Tóth L., Tumpek J., Csípő I., Sipos E., Wooley N., Partanen J., Szegedi G., Oláh É., Sipka S., Korponay-Szabó I. R.
Dátum:2006
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
HLA-DQ
Megjelenés:Alimentary Pharmacology and Therapeutics 24 : 9 (2006), p. 1395-1402. -
További szerzők:Tóth László (1971-) (patológus) Tumpek Judit (1944-) (orvosi laboratóriumi szakorvos) Csípő István (1953-) (vegyész) Sipos E. Wooley, N. Partanen, Jukka Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Oláh Éva (1943-2019) (gyermekgyógyász, klinikai genetikus) Sipka Sándor (1945-) (laboratóriumi szakorvos) Korponay-Szabó Ilma (1959-) (gyermekgyógyász)
Internet cím:elektronikus változat
DOI
Borító:

3.

001-es BibID:BIBFORM028490
Első szerző:Kiss Lajos Sándor
Cím:Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease / Kiss, L. S., Szamosi, T., Molnar, T., Miheller, P., Lakatos, L., Vincze, A., Palatka, K., Barta, Z., Gasztonyi, B., Salamon, A., Horvath, G., Tóth, G. T., Farkas, K., Banai, J., Tulassay, Z., Nagy, F., Szenes, M., Veres, G., Lovasz, B. D., Vegh, Z., Golovics, P. A., Szathmari, M., Papp, M., Lakatos, P. L.
Dátum:2011
ISSN:0269-2813
Megjegyzések:Adalimumab is a fully human monoclonal antibody targeting tumour necrosis factor with proven efficacy in the treatment of Crohn's disease (CD). AIM: To investigate the predictors of medium-term clinical efficacy and mucosal healing during adalimumab therapy, in patients with CD, in specialised centres approved for biological therapy in Hungary. METHODS: Data capture of the 201 CD patients was standardised and prospective (male/female: 112/89, median age: 33.0 years, duration: 8 years). Previous infliximab therapy had been administered in 48% of patients, concomitant steroids in 41%, azathioprine in 69% and combined therapy in 27% of patients. RESULTS: Overall clinical response and remission rates at 24 weeks were 78% and 52%, respectively; at 52 weeks were 69% and 44%, respectively. Endoscopic improvement and healing were achieved in 43% and 24% of patients. In a logistic regression model, clinical efficacy and CRP at week 12, need for combined immunosuppression at induction, shorter disease duration and smoking were identified as independent predictors for 12-month clinical outcome, whereas CRP at week 12, clinical remission at week 24, inflammatory parameters and nonsmoking were associated to endoscopic improvement/healing. Intensification to weekly dosing was needed in 16% of patients. Parallel azathioprine therapy and clinical remission at week 12 were inversely associated with dose escalation. CONCLUSIONS: Clinical efficacy and normalised CRP at week 12 (early deep clinical remission) are associated with medium-term clinical efficacy and mucosal healing during adalimumab therapy, whereas need for combined immunosuppression at induction and smoking status are predictors for non-response. Parallel azathioprine therapy may decrease the probability for dose escalation.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Alimentary Pharmacology & Therapeutics. - 34 : 8 (2011), p. 911-922. -
További szerzők:Szamosi Tamás Molnár Tamás (orvos Szeged) Miheller Pál Lakatos László (Veszprém) Vincze A. (orvos Pécs) Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Barta Zsolt (1964-) (belgyógyász, gasztroenterológus) Gasztonyi Beáta Salamon A. (orvos Zalaegerszeg) Horváth Gábor (orvos Miskolc) Tóth Gábor Tamás Farkas Katalin Banai János Tulassay Zsolt (1944-) (belgyógyász, gasztroenterológus) Nagy Ferenc (orvos Szeged) Szenes Mária Veres Gábor (1969-2020) (csecsemő- és gyermekgyógyász, gasztroenterológus) Lovász Barbara Dorottya Végh Zsuzsanna Golovics Petra Anna Szathmári Miklós Papp Mária (1975-) (belgyógyász, gasztroenterológus) Lakatos Péter (Semmelweis Egyetem)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM042704
035-os BibID:PMID:16197494
Első szerző:Korponay-Szabó Ilma (gyermekgyógyász)
Cím:Coeliac disease case finding and diet monitoring by point-of-care testing / I. R. Korponay-Szabó, T. Raivio, K. Laurila, J. Opre, R. Király, J. B. Kovács, K. Kaukinen, L. Fésüs, M. Mäki
Dátum:2005
ISSN:0269-2813
Megjegyzések:BACKGROUND: Immunoglobulin A class transglutaminase autoantibodies are highly predictive markers of active coeliac disease, a disorder difficult to recognize solely on clinical grounds. AIMS: To develop and evaluate a simple rapid test for point-of-care detection of coeliac autoantibodies. METHODS: The novel whole blood test utilizes the patient's endogenous transglutaminase in red blood cells for detection of transglutaminase-specific immunoglobulin A antibodies present in the blood sample, with normal plasma immunoglobulin A detection as positive test control. We evaluated 284 patients under suspicion of coeliac disease and undergoing jejunal biopsy, and 263 coeliac patients on a gluten-free diet, 383 being tested prospectively in a point-of-care setting. Results were compared with histology, conventional serum autoantibody results and dietary adherence. RESULTS: The rapid test showed 97% sensitivity and 97% specificity for untreated coeliac disease, and identified all immunoglobulin A-deficient samples. Point-of-care testing found new coeliac cases as efficiently as antibody tests in laboratory. Coeliac autoantibodies were detected onsite in 21% of treated patients, while endomysial and transglutaminase antibodies were positive in 20% and 19%, respectively. The positivity rate correlated with dietary lapses and decreased on intensified dietary advice given upon positive point-of-care test results. CONCLUSIONS: Point-of-care testing was accurate in finding new coeliac cases and helped to identify and decrease dietary non-compliance.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Alimentary Pharmacology and Therapeutics. - 22 : 8 (2005), p. 729-737. -
További szerzők:Raivio, Tiina Laurila, Kaija Opre Judit (Kenézy Gyula Kórház) Király Róbert (1975-) (biológus) Kovács J. Béla Kaukinen, Katri Fésüs László (1947-) (orvos biokémikus) Mäki, Markku
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM040343
Első szerző:Molnár T. (orvos)
Cím:Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy / Molnár T., Lakatos P. L., Farkas K., Nagy F., Szepes Z., Miheller P., Horváth G., Papp M., Palatka K., Nyári T., Bálint A., Lőrinczy K., Wittmann T.
Dátum:2013
Megjegyzések:BACKGROUND: Some of the most important questions relating to the use of biological therapy in inflammatory bowel diseases concern the duration of maintenance therapy. AIM: To assess the disease course and frequency of relapse of Crohn's disease (CD) following discontinuation of biological therapy, and to determine predictive factors for relapse. METHODS: One hundred twenty-one CD patients who had achieved clinical remission following 1 year of biological therapy and for whom biological therapy was then discontinued participated in this prospective observational study. Eighty-seven CD patients had received infliximab and 34 adalimumab. The definition of relapse was an increase of >100 points in CDAI to at least a CDAI of 150 points. RESULTS: Biological therapy was restarted within 1 year of treatment cessation in 45% of patients. Logistic regression analysis revealed that previous biological therapy (P = 0.011) and dose intensification during the 1-year course of biological therapy (P = 0.024) were associated with the need for and the time to the restarting of biological therapy. Smoking was observed to have an effect that was not statistically significant (P = 0.053). CONCLUSIONS: Biological therapy was restarted a median of 6 months after discontinuation in almost half of Crohn's disease patients in who had been in clinical remission following 1 year of biological therapy. These results suggest that, in the event of the presence of certain predictive factors, biological therapy should probably be continued for more than 1 year by most patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Alimentary Pharmacology and Therapeutics. - 37 : 2 (2013), p. 225-233. -
További szerzők:Lakatos Péter (Semmelweis Egyetem) Farkas K. Nagy Ferenc (orvos Szeged) Szepes Zoltán Miheller Pál Horváth G. Papp Mária (1975-) (belgyógyász, gasztroenterológus) Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Nyári Tibor Bálint Anita Lőrinczy K. Wittmann Tibor
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM023665
Első szerző:Raivio, Tiina
Cím:Self transglutaminase-based rapid coeliac disease antibody detection by a lateral flow method / T. Raivio, K. Kaukinen, E. Nemes, K. Laurila, P. Collin, J. B. Kovács, M. Mäki, I. R. Korponay-Szabó
Dátum:2006
Megjegyzések:The conventional coeliac disease antibody tests require patient's sera, and are laborious and time-consuming. AIM: To evaluate a newly developed rapid whole blood test in coeliac disease antibody detection, and its suitability for office use. METHODS: Endogenous tissue transglutaminase found in red blood cells in a whole blood fingertip or venous sample is liberated upon haemolysis and complexes with tissue transglutaminase antibodies, if present. The complexes, captured by a lateral flow system, are visualized within 5 min. Stored samples from 121 untreated, 106 treated coeliac disease patients and 107 controls were evaluated and compared with serum endomysium and tissue transglutaminase antibody tests and histology; 150 patients were prospectively tested on site in the doctor's office. RESULTS: The rapid test showed sensitivity (96.7%) comparable with the serum endomysium and tissue transglutaminase antibody tests from stored samples; specificity was slightly lower (93.5%). When tested on site the results were concordant in 96.7% of cases compared with endomysium and tissue transglutaminase antibody results. The test recognized the disappearance of tissue transglutaminase antibodies on a gluten-free diet. CONCLUSIONS: The self tissue transglutaminase-based rapid test can be easily carried out from a fingertip blood sample on site in the physician's office for both coeliac disease case finding and dietary monitoring purposes.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Alimentary Pharmacology & Therapeutics. - 24 : 1 (2006), p. 147-154. -
További szerzők:Kaukinen, Katri Nemes Éva (1957-) (csecsemő- és gyermekgyógyász, gasztroenterológus) Laurila, Kaija Collin, P. B. Kovács Judit Mäki, Markku Korponay-Szabó Ilma (1959-) (gyermekgyógyász)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

7.

001-es BibID:BIBFORM109151
035-os BibID:(scopus)85143485531 (wos)000888150500001
Első szerző:Szajewska, Hania
Cím:Systematic review : early feeding practices and the risk of coeliac disease. A 2022 update and revision / Szajewska Hania, Shamir Raanan, Strózyk Agata, Chmielewska Anna, Zalewski Bartomiej M., Auricchio Renata, Koletzko Sibylle, Korponay-Szabo Ilma R., Mearin M. Luisa, Meijer Caroline, Ribes-Koninckx Carmen, Troncone Riccardo, PreventCD project group
Dátum:2023
ISSN:0269-2813 1365-2036
Megjegyzések:Background: The effects of early feeding practices on the risk of coeliac disease (CD) remain debated. Aims: To update evidence on these practices on the risk of CD and/or CD-related autoimmunity (CDA), defined as anti-transglutaminase or anti-endomysial antibody positivity METHODS: We searched MEDLINE, EMBASE and the Cochrane Library to May 2022 for randomised controlled trials (RCTs) and observational studies. Results: We included 36 publications (30 studies). In the population at genetic risk of developing CD (HLA DQ2/DQ8-positive), exclusive or any breastfeeding and longer breastfeeding duration did not reduce the risk of developing CD/CDA during childhood. While a meta-analysis of four case-control studies showed a decreased risk for CD when gluten was introduced during breastfeeding, this was not shown in RCTs and cohort studies. Age at gluten introduction was not associated with cumulative CD/CDA risk, although two RCTs suggested that earlier gluten introduction was associated with earlier CDA appearance. Evidence from six observational studies suggests that consumption of a higher amount of gluten at weaning and/or thereafter may increase CD risk. There is insufficient evidence to determine the amount of gluten associated with an increased CD/CDA risk. Regarding whether infant feeding practices modulate the risk conferred by different HLA genotypes results were inconsistent. Conclusions: For the population at genetic risk of CD, breastfeeding and age at gluten introduction have no effect on its cumulative incidence during childhood. There is some evidence for an effect of the amount of gluten consumed at weaning and/or thereafter on CD/CDA risk.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
celiac disease
infant fedding
Megjelenés:Alimentary Pharmacology & Therapeutics. - 57 : 1 (2023), p. 8-22. -
További szerzők:Shamir, Raanan (gyermekgyógyász) Stróżyk, Agata Chmielewska, Anna Zalewski, Bartomiej Auricchio, Renata Koletzko, Sibylle Korponay-Szabó Ilma (1959-) (gyermekgyógyász) Mearin, Maria Luisa Meijer, Caroline R. Ribes-Koninckx, Carmen Troncone, Riccardo PreventCD Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM089326
035-os BibID:(WoS)000602715700022 (Scopus)85098011271
Első szerző:Tornai Dávid (hepatológia, biomarker kutatás)
Cím:Editorial : serologic antibodies in primary sclerosing cholangitis - a tell-tale sign of compromised gut-liver immunity? / Tornai Dávid, Papp Mária
Dátum:2021
ISSN:0269-2813 1365-2036
Megjegyzések:Biomarkers provide tools for clinicians to help decision making and in some cases contribute to better understanding of disease pathology. The recent publication from Wunsch et al.1 is an example. It meets a long-standing need for prognostic tools in primary sclerosing cholangitis (PSC) which can reliably predict progression to endstage liver disease or cholangiocarcinoma (CCA) development. This and previous studies2,,3,4 ignite new sparks toward exploration of derangement of the gut-liver axis in PSC and holds promise for the discovery of effective medical therapy that are currently lacking.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
primary sclerosing cholangitis
hepatology
autoimmune liver disease
liver transplantation
biliary tract
liver fibrosis
cholangiocarcinoma
inflammation
Megjelenés:Alimentary Pharmacology and Therapeutics. - 53 : 2 (2021), p. 350-351. -
További szerzők:Papp Mária (1975-) (belgyógyász, gasztroenterológus)
Pályázati támogatás:GINOP-2.3.2-15-2016-00048
GINOP
BO/00232/17/5
Egyéb
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

9.

001-es BibID:BIBFORM077369
035-os BibID:(WoS)000451550300006 (Scopus)85056762710
Első szerző:Ziv-Baran, Tomer
Cím:Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric Crohn's disease / Tomer Ziv-Baran, Séamus Hussey, Malgorzata Sladek, Jorge Amil Dias, Javier Martin de Carpi, Erasmo Miele, Gabor Veres, Paolo Lionetti, Sibylle Koletzko, Federica Nuti, Anders Paerregaard, Kaija-Leena Kolho, Richard K. Russell, Ron Shaoul, Dror Weiner, Rotem Sigall Boneh, Johanna Escher, Lenne Finnby, Dan Turner, Arie Levine
Dátum:2018
ISSN:0269-2813 1365-2036
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Alimentary Pharmacology & Therapeutics. - 48 : 11-12 (2018), p. 1242-1250. -
További szerzők:Hussey, Séamus Sladek, Małgorzata Amil Dias, Jorge Martin de Carpi, Javier Miele, Erasmo Veres Gábor (1969-2020) (csecsemő- és gyermekgyógyász, gasztroenterológus) Lionetti, Paolo Koletzko, Sibylle Nuti, Federica Paerregaard, Anders Kolho, Kaija-Leena Russell, Richard K. Shaoul, Ron Weiner, Dror Sigall Boneh, Rotem Escher, Johanna Finnby, Lenne Turner, Dan Levine, Arie
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.